Bramstedt Katrina A, Ford Paul J
Research Subject Advocate Program, Cleveland Clinic, General Clinical Research Center, OH 44195, USA.
Contemp Clin Trials. 2006 Apr;27(2):161-4. doi: 10.1016/j.cct.2005.11.005. Epub 2006 Jan 4.
The discomfort and suffering of medically refractory organic dystonia has lead to the pursuit of new potential treatment interventions, namely, pallidotomy and deep brain stimulation (DBS). The risks inherent in surgical procedures require a heightened awareness to the need for protecting the welfare of research subjects participating in surgical trials. To this end, excluding patients who are not appropriate candidates is a key part of the trial process. We argue that psychogenic dystonia, a condition that is both difficult to diagnose and difficult to treat, should be an exclusion criterion for DBS therapy, and neurosurgery in general. However, since there exists no definitive test for psychogenic dystonia, researchers must determine fair and just criteria for excluding patients whose dystonia is suspected to be primarily psychogenic.
药物难治性器质性肌张力障碍所带来的不适与痛苦促使人们寻求新的潜在治疗干预措施,即苍白球切开术和脑深部电刺激术(DBS)。外科手术固有的风险要求我们更加重视保护参与外科试验的研究对象的福利。为此,排除不合适的患者是试验过程的关键部分。我们认为,精神性肌张力障碍这种既难以诊断又难以治疗的病症,应该成为DBS治疗以及一般神经外科手术的排除标准。然而,由于目前尚无针对精神性肌张力障碍的确切检测方法,研究人员必须确定公平公正的标准,以排除那些肌张力障碍疑似主要为精神性的患者。